Human Papillomavirus Viruses

Vulvar cancer is an underrecognized gynecologic malignant disease. The incidence of vulvar cancer is 2.3 per 100 000 people in Canada, and is increasing with the rising prevalence of human papillomavirus (HPV). More than 90% of vulvar cancers are squamous cell carcinomas (SCC), mostly diagnosed after age 65 years. Vulvar SCC mimics nonspecific inflammation, which often delays diagnosis. Risk factors include advanced age, HPV infection, lichen sclerosis, smoking, immunodeficiency, and pelvic radiation

Author/s:

Jennifer Davis, Jacob McGee, Anjali Kulkarni

AAP Releases Its Own Childhood and Adolescent Immunization Schedule

Megan George — Mon, 23 Feb 2026 17:20:20 +0000

Date Added:

February 23, 2026

Journal/Publication:

JAMA

Publication Date:

February 13, 2026

URL:

AAP Releases Its Own Childhood and Adolescent Immunization Schedule

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1001/jama.2025.26393

Keywords

Immunization Schedule

Respiratory Syncytial Viruses

Human Papillomavirus Viruses

PMID (1):

41686462

MeSH

Immunization Schedule

Respiratory Syncytial Viruses

Human Papillomavirus Viruses

Updated 2026 childhood immunization guidelines from the AAP. James W. Mold, MD, MPH

The AAP recommends vaccines to protect children against 18 diseases. The updated CDC schedule removed routine recommendations for hepatitis A and B, COVID-19, respiratory syncytial virus, rotavirus, influenza, and meningococcal disease, instead only recommending them for certain groups at high risk of infection or based on shared clinical decision-making. The AAP continues to suggest vaccines for these diseases.

There are also differences regarding administration. For example, the new CDC schedule recommends that children aged 4 to 6 years receive both a measles, mumps, and rubella vaccine and a monovalent varicella vaccine, but the AAP also supports a combination vaccine that covers all 4 viruses. And although the CDC recommends 1 dose of the human papillomavirus virus vaccine at ages 11 to 12 years, the AAP recommends 2 doses starting at ages 9 to 12 years.

Recommendations from the AAP are based on a review of vaccine safety data and the epidemiology of US diseases, the organization said. It added that insurance coverage and liability protection are expected to continue for all vaccines on the CDC schedule—even those no longer considered routine—according to federal officials.

Author/s:

Samantha Anderer

New Cervical Cancer Screening Guidelines From the US Department of Health and Human Services: Strengthening Women’s Preventive Health

Megan George — Tue, 06 Jan 2026 14:29:39 +0000

Date Added:

January 6, 2026

Journal/Publication:

JAMA

Publication Date:

January 5, 2026

URL:

New Cervical Cancer Screening Guidelines From the US Department of Health and Human Services: Strengthening Women’s Preventive Health

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1001/jama.2025.26456

Keywords

cervical cancer

Cancer Screeing

PMID (1):

41489823

MeSH

uterine cervical neoplasms

Papanicolaou Test

early detection of cancer

Uterine Cervical Dysplasia

Human Papillomavirus Viruses

Updated HRSA (2026) guidelines for cervical cancer screening. James W. Mold, MD, MPH

View

Cervical cancer screening is one of the most significant public health accomplishments of the 20th century. Over the last 50 years, incidence and mortality rates from cervical cancer in the US have decreased by more than 50%1 because of widespread use of the Papanicolaou test and later adoption of high-risk human papillomavirus (hrHPV) testing.

Regular screening is critical in detecting disease because women with precancerous cervical intraepithelial neoplasia or early-stage cervical cancer are often asymptomatic. When detected early, 5-year cervical cancer survival is higher than 90%.1 Yet more than half of all cervical cancer diagnoses are made beyond an early stage; 37% when cancer has spread regionally to local lymph nodes and 15% when there are distant cancer metastases. Five-year survival is just 20% for women diagnosed with metastatic disease.1

Cervical cytology (Papanicolaou test) and hrHPV tests are highly effective in detecting early, more treatable disease; however, these modalities are only beneficial for women who undergo recommended screening. Unfortunately, about half of all women diagnosed with cervical cancer have never been screened or are not up-to-date on screening,2 and these women are more likely to present with regional or distant metastatic disease. Overall, approximately 1 in 4 women in the US are not up-to-date on cervical cancer screening.3 Women living in poverty or having fewer years of formal education have even lower screening rates. The direct link between screening and survival illustrates a clear and urgent need to improve cervical cancer screening rates in the US; new self-collection options approved by the US Food and Drug Administration (FDA) provide an opportunity to do so.

Author/s:

Brian Christine, Margaret Bush, Anita Thurakal, Ann M Sheehy

Human Papillomavirus and Cancer

Megan George — Thu, 21 Aug 2025 16:13:34 +0000

Date Added:

August 21, 2025

Journal/Publication:

The New England Journal of Medicine

Publication Date:

July 30, 2025

Issue:

Volume:

393

URL:

Human Papillomavirus and Cancer

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Video

DOI (1):

10.1056/NEJMp2414535

Keywords

Human Papillomavirus Viruses

Uterine Cervical Neoplasms

Papillomavirus Infections

Papillomavirus Vaccines

MeSH

Papillomavirus Vaccines

Papillomavirus Infections

uterine cervical neoplasms

Human Papillomavirus Viruses

This is a 13 ½ minute audio-review of the link between HPV and various cancers and current recommendations regarding HPV immunization. James W. Mold, MD, MPH

Free full text

View

In this Double Take video from the New England Journal of Medicine, Dr. Julie Barzilay discusses the connection between certain strains of human papillomavirus (HPV) and cancer, as well as the evidence to support the safety and efficacy of the HPV vaccine in reducing the risk of cervical neoplasia. Strategies for discussing the HPV vaccine with patients and families are also reviewed.

Author/s:

Julie R. Barzilay, Sarah Feldman, Alison E. Burke, Emily Ling, Scott Williams, Caren G. Solomon

Cervical Cancer Screening

Erin Blanchette — Mon, 13 Nov 2023 16:19:48 +0000

Date Added:

November 14, 2023

Journal/Publication:

JAMA

Publisher:

American Medical Association

Publication Date:

October 27, 2023

URL:

Cervical Cancer Screening

Type:

Patient Education Materials

Format:

Article

DOI (1):

10.1001/jama.2023.21987

Keywords

Human Papillomavirus Viruses

PMID (1):

37889510

MeSH

Human Papillomavirus Viruses

Cervix Uteri

uterine cervical neoplasms

early detection of cancer

Papanicolaou Test

Patient education regarding cervical cancer screening. James W. Mold, MD, MPH

Free full text

View

This JAMA Patient Page discusses screening for cervical cancer, including who should be screened, recommendations for handling positive results, and the prevention of cervical cancer.

Author/s:

Rebecca A. Voelker